{"id":62074,"date":"2024-11-27T12:00:48","date_gmt":"2024-11-27T12:00:48","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/11\/27\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/"},"modified":"2024-11-27T12:00:48","modified_gmt":"2024-11-27T12:00:48","slug":"advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/","title":{"rendered":"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe"},"content":{"rendered":"<div>\n<p align=\"center\"><img decoding=\"async\" data-mce-src=\"\/api\/ImageRender\/DownloadFile?resourceId=6b1f50d8-b18f-4260-ad02-8593b4c82eb9&amp;size=3\" height=\"166.84px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/6b1f50d8-b18f-4260-ad02-8593b4c82eb9\/image1.jpeg\" width=\"374.21px\"><\/p>\n<p align=\"center\"><strong>ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> conditional marketing authorisation in Europe<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\">The conditional marketing authorisation for OCALIVA<sup>\u00ae <\/sup>across the EU and EEA has been revoked with immediate effect<\/li>\n<li style=\"text-align:justify;\">ADVANZ PHARMA is considering next steps, including options to enable continued access for patients<\/li>\n<\/ul>\n<p align=\"justify\"><strong>London, UK \u2013 27\/11\/2024: <\/strong>ADVANZ PHARMA Holdco Limited (ADVANZ PHARMA or the Company), a UK headquartered pharmaceutical company, today announces that following the grant of a temporary suspension, as announced on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QjnKIHegKk4TAIASYzGylJTBQLKc9uagR0NXmFQ_fsKY6uYfsAS-p695LMX8_X1wUBRqG-ISN4Uvy9AYhCoggVj1cAYwIddjMuo8dJRSWQaXLZVU0IYbuyhLNUcGNq22sP5Xf6CImbNL1SZIhsljkCZ9ZN60gCWLLyb8P4soynZZfvwiBgzXKAO9KS7fChot4xus9cOtbulVTnH5XIrVKl44ED7aj2zvuft4cLYSvcmulOa7Ai7NHWxc2t2hUlnjtyHlDQnWDmQtMo_tCUlpTQ==\" rel=\"nofollow\" target=\"_blank\" title=\"5\">5<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qCFM1OWUWr_3tlFTtCf3Wedn34OOAXutdudcec4SesrvsKotXMUHsgk_Tlr3HJgAQWtGid9IIGeaV_Lgse3esa3jF2NHQqlmEVXFVbufiWtpxx9ueP8KPXnsfh04QiNP3D3tot9cfPx8AeRLVzuKAPrDH3yJCUKoQLQq6LH7YQz6lIkCzO6W6ftEZiIITl41OS6BoPYS-teR-3Mvie3R8aeLP9WboFJqIpGkdgQCycV4imjW1uWRb6VCxMw7IYc-PVuB_svUkoSfXBUWgBx0Rw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><sup>th<\/sup><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0jmMjLVZMC6wpMPHx1JWWfAfMBNbXGGVilaOY5Ruj3uV3sVnMHrnb9-3mx6DXOsM-RjcKkXgZkWf815yz74ObDg_oudlnTX8ySmh4NjJyKmv8HDBc6tDRmKwC5Hr4fL8MN7UrWiKKUMR2XrqNT0D0cYuAcdCILZegK_tEmNaHZhEKaShBQdzX3ePEmGHGs9NuHFg-f6YFxBOZjkQ15G-TkvNeF4lTCvn4EIEEqZJNREXyomHHG2odTxTeMcUW9BHbLpz-Z0I_j9z_CFBkFdzdPPd-Wo6Qk60O00RRSBrrQk=\" rel=\"nofollow\" target=\"_blank\" title=\"September 2024\"> September 2024<\/a>, the General Court of the European Union (General Court) has decided <u>not<\/u> to further extend the suspension of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PqRV8CyjE8tdahajTxVJ4s8prYlFBJvXhXmIL7U0heVNkdCBkCTD6Jja42_gCiKojxNQNGp8onl5QAdK_r2cA3MkY9aWlFJCMZuCkZepZ_dj89oKx1XvB9v4x7W_n3K_9HW6ZQbtH4TBrPcUmX-T6mD_zc9JYWmNJErcYMi3tpFkwJqLFzYna0lGQkMIChkS1orEzB-CKwV9rRo0_frve5FPHu5w9ISpSrI8pTc0N8JzVEOnAhRxdHyEHmyDmNRf6mTF4gtekCn3QgnYJeBUnQBlFQ7YmExVagoTqoiE5ctka4vBts_TM0IMbP_koa2UrubYdsnrJUCb8Uw2AWuU6A==\" rel=\"nofollow\" target=\"_blank\" title=\"European Commission (EC) decision\">European Commission (EC) decision<\/a> to revoke the conditional marketing authorisation (CMA) for OCALIVA<sup>\u00ae<\/sup>\u00a0(obeticholic acid) in Europe (EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway) for second-line treatment of patients with the rare liver disease Primary Biliary Cholangitis (PBC). <\/p>\n<p>This means that the EC\u2019s revocation decision is in force, resulting in the CMA for OCALIVA<sup>\u00ae<\/sup> being revoked in Europe (EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway) with immediate effect.<\/p>\n<p align=\"justify\">The General Court Order only assessed whether there were \u201cserious\u201d and \u201cirreparable\u201d or \u201cirreversible\u201d damages to ADVANZ PHARMA caused by the EC decision, and did not assess patient impact or the overall validity of the EC decision. The overall validity of the EC decision is subject to an ongoing annulment procedure at the General Court which has not yet been ruled upon, and is anticipated in 2025.<\/p>\n<p align=\"justify\">Steffen Wagner, CEO at ADVANZ PHARMA, commented: \u201cWe are very disappointed by the General Court\u2019s decision. OCALIVA<sup>\u00ae<\/sup> is a much-needed treatment option for thousands of patients with PBC in Europe. As an FXR agonist, OCALIVA<sup>\u00ae<\/sup> has a different mechanism of action from other treatments and is backed by a wealth of positive real-world evidence, gathered from more than seven years of clinical use. Without OCALIVA<sup>\u00ae<\/sup>, patients could be at increased risk of disease progression, including serious liver harm, liver transplantation or death. ADVANZ PHARMA disagrees with the EC revocation decision and remains committed to supporting patients with PBC and is in discussion with relevant national agencies to enable continued access for patients who rely on this medicine.\u201d<\/p>\n<p align=\"justify\">The European Medicines Agency has referenced the ability for ADVANZ PHARMA to continue \u2013 subject to local laws and regulations \u2013 to supply OCALIVA<sup>\u00ae<\/sup> in Europe on a compassionate access or named patient programme basis for existing patients. ADVANZ PHARMA is committed to supporting patients and will ensure supplies are available depending on national competent authority approved provisions.<\/p>\n<p align=\"justify\">Patients affected should consult their treating physician if they have any questions.<\/p>\n<p align=\"justify\">Further information is available from\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qS5kBf-FslSJxwk7U8uUBZ7sZ9DmiawDgcr5TycIwb6qREvGx5d2yYNyRa2lmZey87xLDX4SzQ_Qqrl18kyJ-BAYamZ3DyBjYcWO7kIfQTahvzKmxaRL4b6vNGR2Uc2DegMtZv2a8Ny-Jsr43Kbe0A==\" rel=\"nofollow\" target=\"_blank\" title=\"medicalinformation@advanzpharma.com\">medicalinformation@advanzpharma.com<\/a>.<\/p>\n<p align=\"justify\"><strong>About OCALIVA<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> and PBC<\/strong><br \/>Primary biliary cholangitis (PBC) is a rare, serious and progressive autoimmune disease that damages the bile ducts in the liver. OCALIVA<sup>\u00ae<\/sup>\u00a0is a film-coated tablet containing obeticholic acid (OCA), a selective and potent agonist of the farnesoid X receptor (FXR) which regulates bile acid, inflammatory, fibrotic and metabolic pathways and decreases intracellular hepatocyte concentrations of bile acids. OCALIVA<sup>\u00ae<\/sup>\u00a0is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.<\/p>\n<p align=\"justify\"><strong>About ADVANZ PHARMA<\/strong><br \/>ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients\u2019 lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network. ADVANZ PHARMA\u2019s product portfolio and pipeline comprises innovative medicines, specialty generics &amp; biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. For more information, please visit our\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OqAsOuXHL21x-YrEmCp7nlYCRyF4U1LgmlJBQ-YvzMmmmHJONGhM8zOpFeaGXMM2B1yQKe7QBc5AGzGmz8GQlA==\" rel=\"nofollow\" target=\"_blank\" title=\"Website\">Website<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zRz8ZfiHRZSCGhjUf3E8Y4QzlW0_j9VE2nJ3nQZ5Hcswtgpldw9GQe9bzf2s8ZPHYuJHcORdGi04fx4pxS_OttlmHWDgbdQvDDQ0f1xuX1c=\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.<\/p>\n<p align=\"left\"><strong>For media enquiries, please contact:<\/strong><br \/>ADVANZ PHARMA<br \/>Courtney Baines<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=onlJDITwm9vZTCfhYxY7YCi-pAZ-PBcJ4yOBFlhcN178GdNdLxDH_RA6721nJcX49DSvXN6Z31xn4LV69HgYv5jYSA7O6yC4Z9V3es8K8hP324ucOjTosZSycS4_maR4C_laQjQvwB1F7pXjwJNs-g==\" rel=\"nofollow\" target=\"_blank\" title=\"courtney.baines@advanzpharma.com\">courtney.baines@advanzpharma.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NjYzYzRhODItMGRhMy00MjE4LThlZWItNDBmN2M1OWM2ZWIzLTcwMDAyNDg4OA==\/tiny\/Advanz-Pharma.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe The conditional marketing authorisation for OCALIVA\u00ae across the EU and EEA has been revoked with immediate effect ADVANZ PHARMA is considering next steps, including options to enable continued access for patients London, UK [&#8230;]\n","protected":false},"author":1,"featured_media":62075,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-62074","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe\" \/>\n<meta property=\"og:description\" content=\"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-27T12:00:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/image1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"857\" \/>\n\t<meta property=\"og:image:height\" content=\"382\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe\",\"datePublished\":\"2024-11-27T12:00:48+00:00\",\"dateModified\":\"2024-11-27T12:00:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/\"},\"wordCount\":756,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/\",\"name\":\"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-11-27T12:00:48+00:00\",\"dateModified\":\"2024-11-27T12:00:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/","og_locale":"en_US","og_type":"article","og_title":"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe","og_description":"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation","og_url":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-11-27T12:00:48+00:00","og_image":[{"width":857,"height":382,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/image1.jpeg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe","datePublished":"2024-11-27T12:00:48+00:00","dateModified":"2024-11-27T12:00:48+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/"},"wordCount":756,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/","url":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/","name":"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-11-27T12:00:48+00:00","dateModified":"2024-11-27T12:00:48+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"ADVANZ PHARMA\u2019s response to the reversal of the suspension of the European Commission decision on the OCALIVA\u00ae conditional marketing authorisation in Europe"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=62074"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62074\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/62075"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=62074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=62074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=62074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}